Effects of astragalus polysaccharides on immunologic function of erythrocyte in chickens infected with infectious bursa disease virus

160 Haline white chickens at 25 days old, negative for antibody to infectious bursa disease virus (IBDV), were randomly allocated into four groups. Chickens in groups 2–4 were infected with 0.3 ml IBDV at 26 days old. Chickens in groups 3 and 4 were injected respectively with 5 and 10 mg astragalus...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 28; no. 34; pp. 5614 - 5616
Main Authors Jiang, Junbing, Wu, Caihong, Gao, Hai, Song, Jiande, Li, Hongquan
Format Journal Article
LanguageEnglish
Published Kidlington Elsevier Ltd 02.08.2010
Elsevier
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:160 Haline white chickens at 25 days old, negative for antibody to infectious bursa disease virus (IBDV), were randomly allocated into four groups. Chickens in groups 2–4 were infected with 0.3 ml IBDV at 26 days old. Chickens in groups 3 and 4 were injected respectively with 5 and 10 mg astragalus polysaccharide (APS) for 6 consecutive days from the first day of infection. At 21, 29, 32, 35 and 38 days old, the blood samples were taken from heart, and erythrocyte-C 3b receptor rosette rate (E-C 3bRR), erythrocyte-C 3b immune complex rosette rate (E-ICRR), erythrocyte rosette forming enhancing rate (ERER) and erythrocyte rosette forming inhibitory rate (ERIR) were measured. The results showed that E-C 3bRR and ERER significantly declined in chicken infected with IBDV ( p < 0.01); E-C 3bRR, E-ICRR and ERER in groups 3 and 4 treated with APS were higher than that in groups 1 and 2 ( p < 0.01), the ERIR in groups 3 and 4 is similar to that in group 1. The results suggest that the immunological function of chicken erythrocytes declines after infected with IBDV and APS obviously enhances the immunological function of chicken erythrocytes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2010.06.025